Literature DB >> 23325090

Proton-pump inhibitor use is associated with low serum magnesium concentrations.

John Danziger1, Jeffrey H William, Daniel J Scott, Joon Lee, Li-wei Lehman, Roger G Mark, Michael D Howell, Leo A Celi, Kenneth J Mukamal.   

Abstract

Although case reports link proton-pump inhibitor (PPI) use and hypomagnesemia, no large-scale studies have been conducted. Here we examined the serum magnesium concentration and the likelihood of hypomagnesemia (<1.6 mg/dl) with a history of PPI or histamine-2 receptor antagonist used to reduce gastric acid, or use of neither among 11,490 consecutive adult admissions to an intensive care unit of a tertiary medical center. Of these, 2632 patients reported PPI use prior to admission, while 657 patients were using a histamine-2 receptor antagonist. PPI use was associated with 0.012 mg/dl lower adjusted serum magnesium concentration compared to users of no acid-suppressive medications, but this effect was restricted to those patients taking diuretics. Among the 3286 patients concurrently on diuretics, PPI use was associated with a significant increase of hypomagnesemia (odds ratio 1.54) and 0.028 mg/dl lower serum magnesium concentration. Among those not using diuretics, PPI use was not associated with serum magnesium levels. Histamine-2 receptor antagonist use was not significantly associated with magnesium concentration without or with diuretic use. The use of PPI was not associated with serum phosphate concentration regardless of diuretic use. Thus, we verify case reports of the association between PPI use and hypomagnesemia in those concurrently taking diuretics. Hence, serum magnesium concentrations should be followed in susceptible individuals on chronic PPI therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325090      PMCID: PMC5682024          DOI: 10.1038/ki.2012.452

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  45 in total

1.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.

Authors:  Michael D Howell; Victor Novack; Philip Grgurich; Diane Soulliard; Lena Novack; Michael Pencina; Daniel Talmor
Journal:  Arch Intern Med       Date:  2010-05-10

2.  Omeprazole and refractory hypomagnesaemia.

Authors:  N Shabajee; E J Lamb; I Sturgess; R W Sumathipala
Journal:  BMJ       Date:  2008-07-10

Review 3.  Magnesium transport in the renal distal convoluted tubule.

Authors:  L J Dai; G Ritchie; D Kerstan; H S Kang; D E Cole; G A Quamme
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

Review 4.  Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance.

Authors:  Mario Barbagallo; Ligia J Dominguez
Journal:  Arch Biochem Biophys       Date:  2006-06-12       Impact factor: 4.013

5.  Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family.

Authors:  Karl P Schlingmann; Stefanie Weber; Melanie Peters; Lene Niemann Nejsum; Helga Vitzthum; Karin Klingel; Markus Kratz; Elie Haddad; Ellinor Ristoff; Dganit Dinour; Maria Syrrou; Søren Nielsen; Martin Sassen; Siegfried Waldegger; Hannsjörg W Seyberth; Martin Konrad
Journal:  Nat Genet       Date:  2002-05-28       Impact factor: 38.330

6.  Omeprazole decreases magnesium transport across Caco-2 monolayers.

Authors:  Narongrit Thongon; Nateetip Krishnamra
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

7.  Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.

Authors:  David C Metz; Mark B Sostek; Philippe Ruszniewski; Christopher E Forsmark; John Monyak; Joseph R Pisegna
Journal:  Am J Gastroenterol       Date:  2007-08-31       Impact factor: 10.864

Review 8.  Hypomagnesaemia due to use of proton pump inhibitors--a review.

Authors:  M T Kuipers; H D Thang; A B Arntzenius
Journal:  Neth J Med       Date:  2009-05       Impact factor: 1.422

Review 9.  Control of magnesium transport in the thick ascending limb.

Authors:  G A Quamme
Journal:  Am J Physiol       Date:  1989-02

10.  Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex.

Authors:  Jianghui Hou; Aparna Renigunta; Martin Konrad; Antonio S Gomes; Eveline E Schneeberger; David L Paul; Siegfried Waldegger; Daniel A Goodenough
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

View more
  55 in total

1.  Proton pump inhibitor associated hypomagnasaemia - a cause for concern?

Authors:  Joe Begley; Trevor Smith; Kirsty Barnett; Paul Strike; Adnan Azim; Claire Spake; Tristan Richardson
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

2.  Proton Pump Inhibitor-Associated C. difficile Infection in a Peritoneal Dialysis Patient.

Authors:  Susan L Ziolkowski; Michelle H Malabanan; Scott E Liebman
Journal:  Perit Dial Int       Date:  2015 Sep-Oct       Impact factor: 1.756

3.  Increased incidence of diuretic use in critically ill obese patients.

Authors:  Emma J de Louw; Pepijn O Sun; Joon Lee; Mengling Feng; Roger G Mark; Leo Anthony Celi; Kenneth J Mukamal; John Danziger
Journal:  J Crit Care       Date:  2015-02-07       Impact factor: 3.425

4.  Association of hypermagnesemia and blood pressure in the critically ill.

Authors:  Leo A Celi; Daniel J Scott; Joon Lee; Rachel Nelson; Seth L Alper; Kenneth J Mukamal; Roger G Mark; John Danziger
Journal:  J Hypertens       Date:  2013-11       Impact factor: 4.844

5.  Hypomagnesemia: a Treatable Cause of Ataxia with Cerebellar Edema.

Authors:  Idoia Rouco Axpe; Javier Almeida Velasco; Jose Guillermo Barreiro Garcia; Jose Manuel Urbizu Gallardo; Beatriz Mateos Goñi
Journal:  Cerebellum       Date:  2017-12       Impact factor: 3.847

6.  Proton Pump Inhibitors Are Not Associated With Acute Kidney Injury in Critical Illness.

Authors:  Joon Lee; Roger G Mark; Leo Anthony Celi; John Danziger
Journal:  J Clin Pharmacol       Date:  2016-09-12       Impact factor: 3.126

7.  Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients.

Authors:  Charlotte Van Ende; Steven Van Laecke; Celine Marechal; Francis Verbeke; Nada Kanaan; Eric Goffin; Raymond Vanholder; Michel Jadoul
Journal:  J Nephrol       Date:  2014-05-10       Impact factor: 3.902

8.  Evaluation of electrolyte repletion in hematopoietic cell transplant patients receiving H-2 receptor antagonists or proton pump inhibitors.

Authors:  K Smith; M L Gatesman; S E Harpe; W Clark
Journal:  Bone Marrow Transplant       Date:  2014-05-12       Impact factor: 5.483

9.  Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.

Authors:  Chandan Vangala; Jingbo Niu; Colin R Lenihan; William E Mitch; Sankar D Navaneethan; Wolfgang C Winkelmayer
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-27       Impact factor: 8.237

10.  The inhibitory role of purinergic P2Y receptor on Mg2+ transport across intestinal epithelium-like Caco-2 monolayer.

Authors:  Narongrit Thongon; Siriporn Chamniansawat
Journal:  J Physiol Sci       Date:  2018-07-21       Impact factor: 2.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.